Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma

Cheng,Bo; Chen,Xuan; Li,Yankang; Huang,Xiaochen; Yu,Jinming

doi:10.3892/or.2018.6706

Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma

Authors:
- Bo Cheng
- Xuan Chen
- Yankang Li
- Xiaochen Huang
- Jinming Yu
View Affiliations

Affiliations: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong 250117, P.R. China, Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: September 13, 2018 https://doi.org/10.3892/or.2018.6706
Pages: 2906-2915

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Monocarboxylate transporter 4 (MCT4) is a membrane transporter of monocarboxylates that has been reported to play an important role in tumorigenesis and progression in several solid tumor types. The present study aimed to investigate its clinical significance in esophageal squamous cell carcinoma (ESCC). After obtaining and analyzing MCT4 mRNA expression data from The Cancer Genome Atlas (TCGA) database, the prognostic potential of MCT4 was evaluated by IHC analysis. The effect of the knockdown of MCT4 by shRNA was also evaluated using Cell Counting Kit-8 (CCK-8) and clonogenic assays, in order to determine whether MCT4 inhibition affected the proliferation and survival ability of ESCC cells. Flow cytometric analysis was used to evaluate apoptosis. Western blot analysis was performed to detect the expression levels of p-Akt, Bax, Bcl-2, cytoplasmic cytochrome c and cleaved caspase-3. MCT4 expression was associated with T stage (P=0.001), N stage (P=0.020) and formalin‑fixed and paraffin-embedded (TNM) stage (P=0.042). Kaplan-Meier survival analysis indicated that patients in the high-MCT4 group had a lower overall survival (OS) rate (P=0.001) and progression-free survival (PFS) rate (P=0.003). The univariate Cox regression analysis and multivariate Cox regression analysis results indicated that MCT4 is an independent predictor of OS (P=0.001 and 0.014) and PFS (P=0.004 and 0.046). Downregulation of MCT4 inhibited cell proliferation and increased apoptosis in vitro. The proliferation rate and clone numbers were decreased and apoptotic rates were increased in the sh-MCT4 groups (all P<0.05). Furthermore, MCT4 knockdown reduced the activation of Akt and increased Bax/Bcl-2 ratios, cytochrome c release and caspase-3 cleavage (all P<0.05). Consequently, MCT4 could serve as a promising biomarker for ESCC to identify patients with poor prognosis.

View Figures

View References

1	Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
2	Abnet CC, Arnold M and Wei WQ: Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
3	Mandard AM, Hainaut P and Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 462:335–342. 2000. View Article : Google Scholar : PubMed/NCBI
4	Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y and Muto M: Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
5	Halestrap AP and Price NT: The proton-linked monocarboxylate transporter (MCT) family: Structure, function and regulation. Biochem J. 343:281–299. 1999. View Article : Google Scholar : PubMed/NCBI
6	Halestrap AP and Wilson MC: The monocarboxylate transporter family - role and regulation. IUBMB Life. 64:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
7	Juel C and Halestrap AP: Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter. J Physiol. 517:633–642. 1999. View Article : Google Scholar : PubMed/NCBI
8	Bonen A: The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur J Appl Physiol. 86:6–11. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bergersen L, Rafiki A and Ottersen OP: Immunogold cytochemistry identifies specialized membrane domains for monocarboxylate transport in the central nervous system. Neurochem Res. 27:89–96. 2002. View Article : Google Scholar : PubMed/NCBI
10	Lunt SY and Vander Heiden MG: Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
11	Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, Ilc K, Roux D, Parks SK, Ferrero JM, et al: Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun. 451:54–61. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kwon JE, Jung WH and Koo JS: The expression of metabolism-related proteins in phyllodes tumors. Tumour Biol. 34:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
13	Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F and Lisanti MP: Using the ‘reverse Warburg effect’ to identify high-risk breast cancer patients: Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 11:1108–1117. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, Chen MS and Liu J: Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol. 141:1151–1162. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T, Kawaguchi M, Marutuska K, Chijiiwa K and Kataoka H: Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int. 34:942–952. 2014. View Article : Google Scholar : PubMed/NCBI
16	Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, et al: MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Reports. 9:2233–2249. 2014. View Article : Google Scholar : PubMed/NCBI
17	Nakayama Y, Torigoe T, Inoue Y, Minagawa N, Izumi H, Kohno K and Yamaguchi K: Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med. 3:25–30. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zhu J, Wu YN, Zhang W, Zhang XM, Ding X, Li HQ, Geng M, Xie ZQ and Wu HM: Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One. 9:e879042014. View Article : Google Scholar : PubMed/NCBI
19	Zhao Z, Han F, He Y, Yang S, Hua L, Wu J and Zhan W: Stromal-epithelial metabolic coupling in gastric cancer: Stromal MCT4 and mitochondrial TOMM20 as poor prognostic factors. Eur J Surg Oncol. 40:1361–1368. 2014. View Article : Google Scholar : PubMed/NCBI
20	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
21	Shlomi T, Benyamini T, Gottlieb E, Sharan R and Ruppin E: Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLOS Comput Biol. 7:e10020182011. View Article : Google Scholar : PubMed/NCBI
22	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
23	Dimmer KS, Friedrich B, Lang F, Deitmer JW and Bröer S: The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 350:219–227. 2000. View Article : Google Scholar : PubMed/NCBI
24	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
25	Parks SK, Chiche J and Pouyssegur J: pH control mechanisms of tumor survival and growth. J Cell Physiol. 226:299–308. 2011. View Article : Google Scholar : PubMed/NCBI
26	Blanker MH, Norg RJ and van der Heide WK: A new approach to patients with lower urinary tract symptoms. Br J Gen Pract. 62:344–345. 2012. View Article : Google Scholar : PubMed/NCBI
27	Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
28	Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
29	Cory S, Huang DC and Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
30	Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI
31	Riedl SJ and Salvesen GS: The apoptosome: Signalling platform of cell death. Nat Rev Mol Cell Biol. 8:405–413. 2007. View Article : Google Scholar : PubMed/NCBI
32	Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
33	Hsieh FY and Lavori PW: Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 21:552–560. 2000. View Article : Google Scholar : PubMed/NCBI
34	Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, et al: Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 227:146–156. 2012. View Article : Google Scholar : PubMed/NCBI